Roslin Cells

What Roslin Cells does

Roslin Cells is a privately held, for-profit biotechnology company headquartered in Edinburgh, United Kingdom, founded in 2006. According to the firm's stated mission, Roslin Cells is focused on creating large numbers of stem cell lines from various cohorts of the population, positioning it within the regenerative medicine and cell therapy manufacturing segment of the UK life sciences industry. The company operates with a small headcount in the 11-50 employee range, consistent with a specialized contract or product-oriented biotech serving research and therapeutic developers.

The firm's business model and product details are not explicitly described in the available data. The company has not disclosed pricing models, named customers, distribution channels, marketing channels, revenue figures, patents, certifications, or strategic partnerships. The only documented financial event is a single funding round on 2018-11-12 in which Roslin Cells received approximately $1,140,244 from Innovate UK (the UK government-backed innovation agency), with Innovate UK acting as lead investor. Innovate UK grants are typically non-dilutive and tied to specific R&D milestones rather than to equity issuance, suggesting the proceeds were used for project-based research activities rather than broad-scale commercial expansion.

The company is led by Janet Downie (CEO) and Kevin Bruce (COO). No further details on board composition, scientific advisory, investors, or operational structure are provided in the input. The data underlying any revenue, growth, or competitive position assessment for Roslin Cells is thin, so any conclusions in this analysis are constrained by limited evidence and should be treated as low confidence.

Name

Roslin Cells

Website

https://roslincells.com

Company type

Private

Founded year

2006

Headcount range

11–50 employees

Short description

Roslin Cells is an Edinburgh-based biotechnology company founded in 2006 that focuses on creating large numbers of stem cell lines from various population cohorts for the regenerative medicine and cell therapy market.

Ownership category

akta.pro rank

Product category

Stem Cell Biobanking

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Stem cell biobanking
• Cell line manufacturing
• Regenerative medicine
• Biomedical research services
• Cell therapy materials

Headquarters

HQ city

Edinburgh

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Core offering

Roslin Cells is a life sciences company focused on creating large numbers of stem cell lines derived from various cohorts of the population. The company produces biological cell line materials for use by biomedical researchers, regenerative medicine developers, and pharmaceutical organisations.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem Cell Line Creation

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights1 record

Broad incumbents

• Takara Bio: Provides stem cell products and reagents, including iPSC-related kits and services. Comparable as a wider-life-sciences-tools provider whose product portfolio overlaps with the stem cell line creation niche that Roslin Cells targets.
• Lonza: Global cell-and-gene-therapy CDMO with cell therapy manufacturing services for autologous and allogeneic therapies. Comparable as a massively scaled incumbent offering the manufacturing capabilities that Roslin Cells also implies in its cell-related services.
• Evotec: Global drug discovery CRO with established iPSC-based screening platforms. Comparable as a higher-scale commercial buyer and developer of iPSC-derived disease models, competing indirectly for pharma stem cell line demand.
• Catalent: Large biologics and cell therapy CDMO providing GMP manufacturing, fill-finish and cell therapy services. Comparable as an established commercial partner for the same stem cell / cell therapy developers that Roslin Cells would serve.

Direct peers

• ReproCELL: Japanese-headquartered stem cell product and services provider offering iPSC and ES cell products, with comparable focus on cataloguing diverse stem cell lines for research and therapeutic customers — directly parallel to Roslin Cells' biobank and stem cell line business.
• Axol Bioscience: UK-based supplier of iPSC-derived cells and disease models for drug discovery. Comparable as a UK-located iPSC products company operating at similar scale and targeting overlapping biopharma customers.
• Cellular Dynamics International (Fujifilm CDI): A leading commercial producer of iPSC-derived cells and tissues for research and drug discovery. Directly comparable to Roslin Cells because both create and distribute human iPSC lines and differentiated cell types to pharma and academic customers.

Emerging players

• Cynata Therapeutics: Clinical-stage stem cell therapy developer using iPSC-derived MSC platform technology. Comparable as a smaller stem cell line / cell therapy company whose manufacturing and cell sourcing roadmap intersects with Roslin Cells' capabilities.

Others

• Roslin Institute (University of Edinburgh): Academic institute renowned for Dolly-the-sheep cloning and regenerative medicine research, located in Edinburgh alongside Roslin Cells. Comparable as a closely connected ecosystem participant providing talent, IP, and scientific credibility relevant to Roslin Cells' operations, though not a commercial competitor.
• CellGenix: Supplier of GMP-grade raw materials, cytokines, and cell therapy manufacturing services. Comparable as an enabling ecosystem participant supplying cell therapy developers — a category adjacent to Roslin Cells' stem cell line offering.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/roslincells
• LinkedInlinkedin.com/company/roslin-cells

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roslin Cells